CVS Health Co. (NYSE:CVS - Free Report) - Equities researchers at Leerink Partnrs cut their FY2024 earnings estimates for shares of CVS Health in a research note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst M. Cherny now anticipates that the pharmacy operator will post earnings of $5.21 per share for the year, down from their previous estimate of $5.47. The consensus estimate for CVS Health's current full-year earnings is $5.32 per share. Leerink Partnrs also issued estimates for CVS Health's Q1 2025 earnings at $1.30 EPS, Q3 2025 earnings at $1.75 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $6.09 EPS, FY2026 earnings at $7.36 EPS and FY2027 earnings at $8.16 EPS.
CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. During the same period in the prior year, the business posted $2.21 earnings per share. The firm's revenue for the quarter was up 6.3% compared to the same quarter last year.
CVS has been the topic of several other research reports. TD Cowen upped their target price on CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a report on Monday, November 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $62.00 price objective on shares of CVS Health in a research note on Tuesday, October 1st. Barclays cut their target price on shares of CVS Health from $75.00 to $71.00 and set an "overweight" rating for the company in a research report on Thursday, November 7th. Royal Bank of Canada lowered their price target on shares of CVS Health from $68.00 to $58.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. Finally, Piper Sandler cut their price objective on CVS Health from $72.00 to $64.00 and set an "overweight" rating for the company in a research report on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $70.50.
Get Our Latest Analysis on CVS
CVS Health Price Performance
Shares of CVS traded up $0.58 on Friday, reaching $44.36. The stock had a trading volume of 21,082,219 shares, compared to its average volume of 11,653,444. The firm has a 50-day moving average of $56.24 and a 200 day moving average of $58.24. The firm has a market capitalization of $55.82 billion, a PE ratio of 11.26, a PEG ratio of 0.89 and a beta of 0.54. CVS Health has a twelve month low of $43.60 and a twelve month high of $83.25. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80.
Hedge Funds Weigh In On CVS Health
A number of hedge funds have recently made changes to their positions in CVS. MidAtlantic Capital Management Inc. purchased a new stake in shares of CVS Health during the 3rd quarter worth about $25,000. Livelsberger Financial Advisory acquired a new position in CVS Health during the third quarter valued at approximately $31,000. Legacy Investment Solutions LLC acquired a new stake in shares of CVS Health in the third quarter worth $31,000. Reston Wealth Management LLC purchased a new position in shares of CVS Health in the 3rd quarter valued at $32,000. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in CVS Health during the 3rd quarter worth $33,000. Institutional investors and hedge funds own 80.66% of the company's stock.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Read More
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.